SCHEMBL7026359

SCHEMBL7026359

COc1cc(CCNC(=O)C(NS(C)(=O)=O)C(C)C)cc(Br)c1OCC#CC1CC1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
KMT2A Q03164 5/20 0.35
MEN1 O00255 4/20 0.35
ALOX15 P16050 1/20 0.34
TSHR P16473 1/20 0.34
HSD17B10 Q99714 1/20 0.34
RAB9A P51151 1/20 0.34
ALDH1A1 P00352 2/20 0.33
HTT P42858 2/20 0.33
CYP1A2 P05177 1/20 0.33
CYP3A4 P08684 1/20 0.33
MAPT P10636 1/20 0.33
CYP2C9 P11712 1/20 0.33
CYP2C19 P33261 1/20 0.33
ICMT O60725 1/20 0.33
APOBEC3A P31941 1/20 0.33
APOBEC3G Q9HC16 1/20 0.33
MITF O75030 1/20 0.33
BRD4 O60885 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7023002 0.94 LMNA (0.41) LMNASMN1; SMN2KMT2AMEN1RAB9A
SCHEMBL7030081 0.93 LMNA (0.38) LMNASMN1; SMN2KMT2AMEN1ALOX15
SCHEMBL7074832 0.86 LMNA (0.40) LMNASMN1; SMN2KMT2AMEN1RAB9A
SCHEMBL7025592 0.85 LMNA (0.38) LMNASMN1; SMN2KMT2AMEN1ALOX15
SCHEMBL7030800 0.83 LMNA (0.37) LMNASMN1; SMN2KMT2AMEN1RAB9A
SCHEMBL7025743 0.83 KMT2A (0.39) LMNASMN1; SMN2KMT2AMEN1ALDH1A1
SCHEMBL7024985 0.80 SMN1; SMN2 (0.39) LMNASMN1; SMN2KMT2AMEN1RAB9A
SCHEMBL6333401 0.80 MMP1 (0.44) LMNAKMT2AMEN1RAB9AALDH1A1
SCHEMBL7101411 0.79 MEN1 (0.51) LMNASMN1; SMN2KMT2AMEN1HSD17B10
SCHEMBL7028093 0.77 LMNA (0.37) LMNASMN1; SMN2KMT2AMEN1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030229228-A1 Novel alpha-sulfin-and alpha-sulfonamino acid amides SYNGENTA CROP PROTECTION, INC. 2003-12-11 US disclosed
EP-1274678-A1 NOVEL ALPHA-SULFIN- AND ALPHA-SULFONAMIDO ACID AMIDES Syngenta Participations AG (CH) 2003-01-15 EP disclosed
WO-2001079159-A1 NOVEL α-SULFIN- AND α-SULFONAMINO ACID AMIDES SYNGENTA PARTICIPATIONS AG (CH) 2001-10-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030229228-A1 Novel alpha-sulfin-and alpha-sulfonamino acid amides ARSA, STS, CBR1 LMNA 4568/4885SMN1; SMN2 1574/4885KMT2A 2446/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.